Sugi Predict

Sugi Predict / Compounds / SCHEMBL6741887

SCHEMBL6741887

SCHEMBL6741887

CC(=O)NC(CO)CSc1c(F)c(Oc2cccc(C3=NCCN3C)c2)nc(Oc2cc(C#N)ccc2OCc2ccccc2)c1F

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 8/20 0.41
▸ F2 P00734 7/20 0.41
▸ PTGER1 P34995 2/20 0.34
▸ PDCD1 Q15116 7/20 0.33
▸ CD274 Q9NZQ7 7/20 0.33
▸ PLG P00747 1/20 0.33
▸ PLAU P00749 1/20 0.33
▸ PLAT P00750 1/20 0.33
▸ F7 P08709 1/20 0.32
▸ F3 P13726 1/20 0.32
▸ SLC6A9 P48067 1/20 0.32
▸ GPR34 Q9UPC5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7413407 0.88 F2 (0.47) F10F2PTGER1PLGPLAU
SCHEMBL6744057 0.85 F2 (0.40) F10F2PTGER1PDCD1CD274
SCHEMBL6738071 0.83 MRGPRX4 (0.36) PTGER1PDCD1CD274SLC6A9
SCHEMBL8060516 0.81 F2 (0.47) F10F2PTGER1PLGPLAU
SCHEMBL6578675 0.80 F2 (0.47) F10F2PTGER1PLAU
SCHEMBL7414461 0.79 F2 (0.49) F10F2PTGER1PLGPLAU
SCHEMBL6593254 0.79 F10 (0.44) F10F2PTGER1PDCD1CD274
SCHEMBL6593401 0.79 F2 (0.44) F10F2PTGER1PLGPLAU
SCHEMBL6597090 0.78 F2 (0.48) F10F2PTGER1PLGPLAU
SCHEMBL6591417 0.78 F2 (0.48) F10F2PTGER1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686367-B2 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2004-02-03 — — US disclosed
US-20030149040-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2003-08-07 — — US disclosed
US-6559147-B2 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example BERLEX LABORATORIES, INC. 2003-05-06 — — US disclosed
US-6552030-B2 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine BERLEX LABORATORIES, INC. 2003-04-22 — — US disclosed
US-6495574-B2 THROMBOSIS DISEASES BERLEX LABORATORIES, INC. 2002-12-17 — — US disclosed
US-6495684-B2 INHIBIT HUMAN FACTOR XA; TREATING DISEASES CHARACTERIZED BY THROMBOTIC ACTIVITY; FOR EXAMPLE 3-((3,5-DIFLUORO-6-(3-(1-METHYLIMIDAZOLIN-2-YL)PHENOXY)-4-(2,3 -DIHYDROXYPROPOXY)PYRIDIN-2-YL)OXY)-4-HYDROXYBENZAMIDINE BERLEX LABORATORIES, INC. 2002-12-17 — — US disclosed
US-6492376-B2 3-((3,5-DIFLUORO-6-(3-(1-METHYLIMIDAZOLIN-2-YL)PHENOXY)-4 -(2,3 -DIHYDROXYPROPOXY)PYRIDIN-2-YL)OXY)-4-HYDROXYBENZAMIDINE, FOR EXAMPLE BERLEX LABORATORIES, INC. 2002-12-10 — — US disclosed
US-20010044536-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants PHILLIPS GARY B (US) 2001-11-22 — — US disclosed
US-20010044537-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2001-11-22 — — US disclosed
US-20010025108-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2001-09-27 — — US disclosed
US-20010023291-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2001-09-20 — — US disclosed
US-20010023292-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2001-09-20 — — US disclosed
EP-1131315-A1 POLYHYDROXYLATED HETEROCYCLIC DERIVATIVES AS ANTI-COAGULANTS BERLEX LABORATORIES, INC. (US) 2001-09-12 — — EP disclosed
US-6262088-B1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants BERLEX LABORATORIES, INC. 2001-07-17 — — US disclosed
WO-2000031068-A1 POLYHYDROXYLATED HETEROCYCLIC DERIVATIVES AS ANTI-COAGULANTS BERLEX LABORATORIES, INC. (DE) 2000-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023291-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, F8, SERPINC1 F10 8/4885F2 1/4885PTGER1 527/4885
US-20010044536-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, SERPINC1, F11 F10 9/4885F2 1/4885PTGER1 426/4885
US-20010044537-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, SERPINC1, F11 F10 9/4885F2 1/4885PTGER1 426/4885
US-20030149040-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, SERPINC1, F8 F10 9/4885F2 1/4885PTGER1 474/4885
US-20010025108-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, SERPINC1, F8 F10 7/4885F2 1/4885PTGER1 383/4885
US-20010023292-A1 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants F2, SERPINC1, F8 F10 8/4885F2 1/4885PTGER1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.